CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology
CareDx and Dovetail Genomics have announced a strategic partnership to advance HLA genotyping for organ and stem cell transplant matching. The collaboration combines CareDx's AlloSeq Tx 17, the first HLA typing solution covering 17 loci, with Dovetail's Hi-C LinkPrep technology to achieve high-resolution genotyping and haplotyping without family studies. The partnership includes an Early Access Program for HLA labs to evaluate innovative donor-recipient matching methods. The combined technology's performance will be presented at the 50th annual ASHI meeting.
CareDx e Dovetail Genomics hanno annunciato una partnership strategica per avanzare nel genotipizzazione HLA per il matching di trapianti di organi e cellule staminali. La collaborazione unisce il AlloSeq Tx 17 di CareDx, la prima soluzione di tipizzazione HLA che copre 17 loci, con la tecnologia Hi-C LinkPrep di Dovetail per raggiungere una genotipizzazione e haplotipizzazione ad alta risoluzione senza studi familiari. La partnership include un Programma di Accesso Anticipato per i laboratori HLA per valutare metodi innovativi di matching donatore-ricevente. Le prestazioni della tecnologia combinata saranno presentate al 50° incontro annuale dell'ASHI.
CareDx y Dovetail Genomics han anunciado una asociación estratégica para avanzar en la genotipificación HLA para el emparejamiento de trasplantes de órganos y células madre. La colaboración combina el AlloSeq Tx 17 de CareDx, la primera solución de tipificación HLA que cubre 17 loci, con la tecnología Hi-C LinkPrep de Dovetail para lograr una genotipificación y haplotipificación de alta resolución sin estudios familiares. La asociación incluye un Programa de Acceso Anticipado para que los laboratorios de HLA evalúen métodos innovadores de emparejamiento donante-receptor. El rendimiento de la tecnología combinada se presentará en la 50ª reunión anual de ASHI.
CareDx와 Dovetail Genomics는 장기 및 줄기세포 이식 매칭을 위한 HLA 유전자형 분석을 발전시키기 위한 전략적 파트너십을 발표했습니다. 이 협업은 CareDx의 AlloSeq Tx 17를 결합하여 17개 위치를 포함한 최초의 HLA 타입 솔루션과 Dovetail의 Hi-C LinkPrep 기술을 함께 사용하여 가족 연구 없이 고해상도 유전자형 분석 및 하플로타입 분석을 달성합니다. 이 파트너십에는 HLA 실험실이 혁신적인 기증자-수혜자 매칭 방법을 평가할 수 있는 조기 접근 프로그램이 포함됩니다. 결합된 기술의 성능은 제50회 연례 ASHI 회의에서 발표될 예정입니다.
CareDx et Dovetail Genomics ont annoncé un partenariat stratégique pour avancer dans la génotypage HLA pour le matching des greffes d’organes et de cellules souches. La collaboration associe le AlloSeq Tx 17 de CareDx, la première solution de typage HLA couvrant 17 loci, à la technologie Hi-C LinkPrep de Dovetail afin d’obtenir un génotypage et un haplotypage haute résolution sans études familiales. Le partenariat comprend un programme d'accès anticipé pour que les laboratoires HLA évaluent des méthodes innovantes de correspondance donneur-recepteur. Les performances de la technologie combinée seront présentées lors de la 50e réunion annuelle de l’ASHI.
CareDx und Dovetail Genomics haben eine strategische Partnerschaft angekündigt, um die HLA-Genotypisierung für die Übereinstimmung von Organ- und Stammzelltransplantationen voranzutreiben. Die Zusammenarbeit vereint AlloSeq Tx 17 von CareDx, die erste HLA-Typisierungslösung, die 17 Loci abdeckt, mit der Hi-C LinkPrep Technologie von Dovetail, um eine hochauflösende Genotypisierung und Haplotypisierung ohne Familienuntersuchungen zu erzielen. Die Partnerschaft umfasst ein Early Access-Programm für HLA-Labore zur Bewertung innovativer Methoden zur Spender-Empfänger-Matching. Die Leistung der kombinierten Technologie wird auf dem 50. jährlichen ASHI-Treffen präsentiert.
- First-to-market advantage with AlloSeq Tx 17 covering 17 loci
- Strategic partnership enhances transplant matching capabilities
- New technology eliminates need for family genotyping studies
- None.
Insights
The strategic partnership between CareDx and Dovetail Genomics represents a significant advancement in transplant matching technology. The integration of Hi-C LinkPrep technology with AlloSeq Tx 17 addresses a critical challenge in transplantation - achieving high-resolution HLA typing without family studies. This collaboration could substantially improve transplant success rates through more precise donor-recipient matching.
The key innovation lies in the combination of AlloSeq Tx 17's coverage of 17 loci with LinkPrep's ability to determine complete HLA haplotypes using short-read sequencing. This eliminates the need for family studies and imputation approaches, potentially reducing time and costs while improving accuracy. The technology's ability to provide direct phasing information from linked long-range reads represents a significant technical advantage over current methods.
For the transplant community, this partnership could lead to more successful matches and better patient outcomes. Early access program participants will gain a competitive advantage in evaluating these innovative matching methods, potentially establishing new standards in transplant medicine.
Partnership Includes Early Access Program Enabling HLA Labs to be at the Forefront of Innovative Solutions for Donor-Recipient Matching
New Data at Annual American Society for Histocompatibility and Immunogenetics Meeting Shows AlloSeq and LinkPrep Technology Enables High-Resolution Genotyping and Haplotyping without Family Studies
HLA labs will be able to participate in an Early Access Program using CareDx’s NGS-based AlloSeq™ Tx 17 HLA typing solution incorporating Dovetail Genomics’ cutting-edge Hi-C LinkPrep™ technology to achieve high-resolution genotyping and haplotyping without the need for family genotyping studies. The addition of haplotyping has the potential to improve the likelihood of long-term successful donor-recipient matching.
“This collaboration reflects CareDx’s commitment to innovation in the transplant field, highlighted by our industry first with AlloSeq Tx 17, the first HLA typing solution to cover 17 loci,” said John W. Hanna, CareDx President and CEO. “Through this partnership, HLA labs will gain early access to cutting-edge solutions, positioning them at the forefront of evaluating innovative donor-recipient matching methods.”
CareDx’s AlloSeq Tx 17 is the market-leading NGS-based, HLA typing solution that uses an innovative hybrid-capture workflow to efficiently streamline donor matching studies in HLA typing while providing expanded gene content, beyond 11 classical HLA loci, for more in-depth results. Dovetail Genomic’s LinkPrep technology introduces a groundbreaking method for generating comprehensive HLA haplotypes. LinkPrep technology is a next-generation rapid Hi-C method that uses short-read sequencing technology to provide direct phasing information from linked long-range reads without relying on any imputation approaches. This enables long distance inter-locus phasing and haplotype determination. Combining AlloSeq Tx with LinkPrep offers researchers the opportunity to evaluate the benefits of high precision and comprehensive HLA haplotypes for donor-recipient matching.
“We believe that Dovetail Genomic’s LinkPrep technology’s unique ability to capture haplotype-aware genetic variation will be a game-changer for applications like HLA testing,” expressed Matt Easterday, Ph.D., J.D., CEO of Dovetail Genomics. “The ability to haplotype through the entire HLA region offers the transplant community an important new tool for optimizing transplant matching.”
The performance of the combined AlloSeq Tx and LinkPrep technology on clinical study samples will be showcased at the 50th annual American Society for Histocompatibility and Immunogenetics (ASHI) meeting in both a poster session and a CareDx symposium titled “Future of Transplant Solutions: Innovation Across the Pre-and Post-Transplant Journey” on October 23, 2024. HLA labs interested in participating in the early access program are encouraged to reach out to their CareDx representative.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in
About Dovetail Genomics
Dovetail Genomics, a subsidiary of Cantata Bio and an Edenroc Sciences company, is a leading provider of genomics solutions focused on understanding the complex organization of the genome. Through Dovetail Genomics' proprietary proximity ligation technologies, the 3D architecture of the genome is captured alongside primary sequence information using standard next-generation sequencing (NGS) approaches. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing, and microbiome analysis in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more. For more information on Dovetail, its technology, and service offerings, visit www.dovetailgenomics.com. Follow Dovetail on X/Twitter: @DTGenomics.
Forward Looking Statements for CareDx, Inc.
This press release includes forward-looking statements related to CareDx, Inc. and its strategic partnership with Dovetail Genomics, including statements regarding the partnership’s ability to drive innovation, the potential benefits and results that may be achieved with AlloSeq and other CareDx products, and the data to be presented at the annual American Society for Histocompatibility and Immunogenetics (ASHI) meeting. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of the strategic partnership or AlloSeq and other CareDx products; risks that the data to be presented at the ASHI may not follow the agenda as stated in this press release; risks that the findings in the studies supporting the data may be inaccurate; general economic and market factors; and other risks discussed in CareDx’s filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023997211/en/
CareDx, Inc.
Media Contacts
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investor@caredx.com
Dovetail Genomics
Vikki Herrera
Oak Street Communications for Dovetail Genomics
pr@cantatabio.com
Source: CareDx, Inc.
FAQ
What is the purpose of CareDx and Dovetail Genomics' partnership for CDNA?
What unique feature does CareDx's AlloSeq Tx 17 (CDNA) offer in transplant matching?
When will CareDx (CDNA) present the new transplant matching technology results?
